Clinical efficacy and mechanisms of biologics for chronic . . . outcomes of biologic therapy versus endoscopic sinus surgery, and discuss therapies in development and future directions (J Allergy Clin Immunol 2025;155:1401-10 ) Key words: Chronic rhinosinusitis, nasal polyp, CRSwNP, CRSsNP, biologic, benralizumab, dupilumab, mepolizumab, omalizumab, tezepelumab Chronic rhinosinusitis (CRS) encompasses a
Tezepelumab for Severe Chronic Rhinosinusitis with Nasal Polyps 2025-03-27 DOI: 10 1056 NEJMdo007940 In patients with chronic severe rhinosinusitis and nasal polyps, tezepelumab therapy led to greater reductions in polyp size and nasal congestion and less
Real-world Outcomes Following Biologic Initiation in US . . . This study aims to characterize biologic use and real-world outcomes, including medication use and nasal polyps (NP) surgeries, following biologic treatment in US patients with CRSwNP Methods: This retrospective cohort study analyzed linked data from IQVIA longitudinal prescription and medical claims databases (July 2018-June 2023)
Ultra-long-acting biological therapy for chronic . . . - The Lancet Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and particularly severe subset of sinonasal inflammatory disease that is characterised by benign outgrowths of the inflamed mucosa The management framework of CRSwNP substantially shifted with the introduction of biological agents 1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic
Dupixent Outperforms Xolair in First-Ever Head-to-Head Trial . . . Key achievements include a 1 60-point greater reduction in nasal polyp size and an 8 0-point superior improvement in smell identification compared to Xolair Dupixent also showed significant advantages in nasal congestion reduction, symptom severity, and quality of life measures